AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|AAPL275.15-18.02 (-6.15%) ▼|ABBV243.14+8.25 (+3.51%) ▲|ABT93.24+2.75 (+3.04%) ▲|ACN125.82-3.33 (-2.58%) ▼|ADBE193.41-3.14 (-1.60%) ▼|AMAT668.00+79.04 (+13.42%) ▲|AMD532.57+13.52 (+2.60%) ▲|AMGN352.82+1.43 (+0.41%) ▲|AMT168.72-5.74 (-3.29%) ▼|AMZN227.01-7.36 (-3.14%) ▼|AVGO378.91-3.17 (-0.83%) ▼|AXP342.46-0.10 (-0.03%) ▼|BA218.12-2.13 (-0.97%) ▼|BAC58.19+0.46 (+0.80%) ▲|BKNG177.05-4.23 (-2.33%) ▼|BLK971.92-10.68 (-1.09%) ▼|BMY55.39+0.39 (+0.71%) ▲|BNY145.43+1.87 (+1.30%) ▲|BRK-B487.81-7.00 (-1.41%) ▼|C144.98+1.39 (+0.97%) ▲|CAT1,057.01+62.56 (+6.29%) ▲|CL91.06-0.82 (-0.89%) ▼|CMCSA22.69+0.05 (+0.22%) ▲|COF204.90+4.42 (+2.20%) ▲|COP106.41-0.51 (-0.48%) ▼|COST942.24-18.73 (-1.95%) ▼|CRM150.19-2.57 (-1.68%) ▼|CSCO118.97-0.77 (-0.64%) ▼|CVS104.66+2.79 (+2.74%) ▲|CVX172.24+0.79 (+0.46%) ▲|DE630.76+30.01 (+5.00%) ▲|DHR193.21+4.34 (+2.30%) ▲|DIS98.05-3.07 (-3.04%) ▼|DUK127.11+0.58 (+0.46%) ▲|EMR145.34+3.90 (+2.76%) ▲|FDX329.44+12.61 (+3.98%) ▲|GD344.70+0.38 (+0.11%) ▲|GE371.36+5.48 (+1.50%) ▲|GEV1,085.47+27.82 (+2.63%) ▲|GILD123.84-1.31 (-1.05%) ▼|GM78.53-0.42 (-0.53%) ▼|GOOG342.19-2.84 (-0.82%) ▼|GOOGL343.71-1.57 (-0.45%) ▼|GS1,065.09-11.82 (-1.10%) ▼|HD345.00+2.14 (+0.62%) ▲|HON231.24+3.82 (+1.68%) ▲|IBM258.27-4.69 (-1.78%) ▼|INTC132.87+0.96 (+0.73%) ▲|INTU255.07-7.26 (-2.77%) ▼|ISRG399.69-2.14 (-0.53%) ▼|JNJ244.88+3.88 (+1.61%) ▲|JPM335.12+1.67 (+0.50%) ▲|KO80.42-0.18 (-0.22%) ▼|LIN522.28+6.55 (+1.27%) ▲|LLY1,127.69+10.43 (+0.93%) ▲|LMT505.02+13.38 (+2.72%) ▲|LOW221.93+0.48 (+0.22%) ▲|LRCX401.82+27.00 (+7.20%) ▲|MA488.92-5.49 (-1.11%) ▼|MCD264.54-9.34 (-3.41%) ▼|MDLZ61.20-0.54 (-0.87%) ▼|MDT80.52+0.39 (+0.49%) ▲|META542.87-14.93 (-2.68%) ▼|MMM167.97+2.06 (+1.24%) ▲|MO73.21+1.14 (+1.58%) ▲|MRK125.45+4.85 (+4.02%) ▲|MS221.04+1.18 (+0.54%) ▲|MSFT352.83-12.62 (-3.45%) ▼|MU1,213.56+165.64 (+15.81%) ▲|NEE87.70+0.08 (+0.09%) ▲|NFLX70.90-0.95 (-1.32%) ▼|NKE40.90-0.92 (-2.20%) ▼|NOW89.52-4.28 (-4.56%) ▼|NVDA195.74-3.17 (-1.59%) ▼|ORCL152.46-5.07 (-3.22%) ▼|PEP139.52-2.75 (-1.93%) ▼|PFE23.67-0.37 (-1.54%) ▼|PG148.50-3.54 (-2.33%) ▼|PLTR107.27-6.24 (-5.50%) ▼|PM178.93+1.62 (+0.91%) ▲|QCOM204.90+7.58 (+3.84%) ▲|RTX186.59+1.53 (+0.83%) ▲|SBUX103.16-0.36 (-0.35%) ▼|SCHW89.44-1.95 (-2.13%) ▼|SO95.91+0.13 (+0.14%) ▲|SPG225.49+3.34 (+1.50%) ▲|T22.42+0.05 (+0.22%) ▲|TMO505.75+13.55 (+2.75%) ▲|TMUS181.57+0.78 (+0.43%) ▲|TSLA375.12-0.35 (-0.09%) ▼|TXN311.81+8.70 (+2.87%) ▲|UBER72.25-1.60 (-2.17%) ▼|UNH415.53+9.73 (+2.40%) ▲|UNP267.73+7.77 (+2.99%) ▲|UPS109.31+3.17 (+2.99%) ▲|USB61.21+1.10 (+1.83%) ▲|V330.52-1.71 (-0.51%) ▼|VZ46.07+0.39 (+0.85%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.78-3.23 (-2.71%) ▼|XOM137.55+0.65 (+0.47%) ▲|
27.9 C
New York
Thursday, June 25, 2026

Tag: result

newssourceFORcompanyinformationcontent1marketreleases

GoveeLife Launches Smart Countertop Ice Maker 2 Pro for Iced Coffee and Summer Hosting

The bullet ice maker delivers first ice in as fast as 3 minutes, up to 47 lb of daily ice production, and up to...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

Solidion Technology Granted 7 New Patents on Composite Anode Materials For Batteries Targeting Humanoid Robots, Space-Based Artificial Intelligence Data Centers and the Lunar Economy

 The newly granted patents further strengthen an already globally leading portfolio of patents on anode materials for high-energy and fast-charging lithium batteriesDALLAS, June 8,...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Calix, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CALX

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia

BANDUNG, Indonesia, June 8, 2026 /PRNewswire/ -- TotalEnergies ENEOS successfully completed Phase 2 of a rooftop solar photovoltaic (PV) project with PT. Perusahaan Industri Ceres...

The OREO Brand & BTS Movement is On! Introducing the Limited Edition OREO & BTS Cookies

BTS is sharing a taste of their Korean roots through a new OREO cookie they created.The OREO cookie offers a taste of BTS's home...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

Dietz & Watson Expands Its Premium Deli Chicken Lineup with Launch of Heritage Roast and Cantina Chicken Breast at IDDBA 2026

New sliced-to-order flavors deliver comforting tradition and vibrant, globally inspired taste 
New sliced-to-order flavors deliver comforting tradition and vibrant, globally inspired taste

BW IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResult

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers